Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast
FILE - A sign for Eli Lilly & Co. appears outside their corporate headquarters in Indianapolis on April 26, 2017. , and the drugmaker came out with a mostly better-than-expected 2025 forecast.
Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while taking the injections. They compete withfrom the Danish drugmaker Novo Nordisk, which also reported strong sales growth on Wednesday.
Earnings Medication Diabetes Health Obesity Business Article 118526193
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly Cuts 2024 Revenue Forecast Amid Softer Demand for Weight Loss and Diabetes DrugsEli Lilly, a leading pharmaceutical company, reduced its 2024 revenue outlook due to lower-than-expected sales for its weight loss and diabetes medications. The company now predicts annual revenue of around $45 billion, down from its previous estimate. This downgrade reflects the slower-than-anticipated growth of incretin drugs, a class that includes Mounjaro and Zepbound, which are key products for Eli Lilly.
Read more »
Eli Lilly Cuts 2024 Revenue Forecast Amid Lower-Than-Expected Demand for Obesity and Diabetes DrugsEli Lilly has downgraded its 2024 revenue projection due to weaker-than-anticipated demand for its weight loss and diabetes medications. The company cites a slowdown in growth and lower-than-expected inventory levels as contributing factors.
Read more »
Eli Lilly Cuts 2024 Revenue Guidance as Demand for Weight Loss and Diabetes Drugs SlowsEli Lilly & Co., a leading pharmaceutical company, has lowered its 2024 revenue expectations due to slower-than-anticipated growth in demand for its obesity and diabetes medications. The company attributes the revised forecast to factors such as market growth not meeting initial projections and lower-than-expected channel inventory levels at year-end.
Read more »
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soarsThe results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.
Read more »
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall shortZepbound and Mounjaro have now underperformed expectations for two straight quarters.
Read more »
2024 Golden Globe Awards Fashion Roundup + Faby's Best of 2024This article covers the red carpet fashion at the 2024 Golden Globe Awards, highlighting standout looks from Zendaya, Janelle James, Sheryl Lee Ralph, and Rihanna. It also promotes voting for various categories in The Fabys Awards of 2024, including Best Wig Hairstylist, Best Natural Hairstylist, Best Makeup Artist, Best Stylist, and Most Fashionable Couple.
Read more »